REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Aug 18, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-08-16

Reporting Person: VAGELOS P ROY (Director, Chairman of the Board)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-16	Common Stock	G	84613	$0.0	Disposed	329543	Direct
2017-08-16	Common Stock	M	153969	$21.92	Acquired	483512	Direct
2017-08-16	Common Stock	F	7159	$471.41	Disposed	476353	Direct
2017-08-16	Common Stock	F	75406	$471.41	Disposed	400947	Direct
2017-08-16	Common Stock	S	10986	$470.17	Disposed	389961	Direct
2017-08-17	Common Stock	S	1305	$470.0	Disposed	388656	Direct
2017-08-18	Common Stock	S	2900	$470.15	Disposed	385756	Direct
2017-07-03	Common Stock	G	422	$0.0	Disposed	150285	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-16	Non-Qualified Stock Option (right to buy)	$21.92	M	153969	Disposed	2017-12-17	Common Stock (153969)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2300	Indirect
Common Stock	83652	Indirect
Common Stock	1203	Indirect

Footnotes

F1: Represents volume-weighted average price of sales of 10,986 shares of Company stock on August 16, 2017 at prices ranging from $470.00 to $470.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2017 at each separate price.

F2: Represents volume-weighted average price of sales of 1,305 shares of Company stock on August 17, 2017 at prices ranging from $470.00 to $470.03. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 17, 2017 at each separate price.

F3: Represents volume-weighted average price of sales of 2,900 shares of Company stock on August 18, 2017 at prices ranging from $470.00 to $470.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 18, 2017 at each separate price.

F4: By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.

F5: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.